BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16755223)

  • 41. In vitro comparative antileukemic activity of various glucocorticoids in childhood acute leukemia.
    Styczyński J; Wysocki M; Balwierz W; Rokicka-Milewska R; Matysiak M; Balcerska A; Kowalczyk A; Wachowiak J; Sońta-Jakimczyk D; Chybicka A
    Neoplasma; 2002; 49(3):178-83. PubMed ID: 12098004
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Polygenic Pharmacogenomic Markers as Predictors of Toxicity Phenotypes in the Treatment of Acute Lymphoblastic Leukemia: A Single-Center Study.
    Larkin T; Kashif R; Elsayed AH; Greer B; Mangrola K; Rafiee R; Nguyen N; Shastri V; Horn B; Lamba JK
    JCO Precis Oncol; 2023 Mar; 7():e2200580. PubMed ID: 36952646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Recent progress in the treatment of acute leukemia].
    Kimura Y
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):895-901. PubMed ID: 12894700
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intensified chemotherapy for childhood lymphoblastic leukemia: modifications and results of induction treatment in St. Jude Study XI.
    Rivera GK; Kalwinsky DK; Mirro J; Pui CH; Abromowitch M; Ochs J; Furman W; Santana V; Look AT; Dow LW
    An Esp Pediatr; 1988 Oct; 29 Suppl 34():83-8. PubMed ID: 3214044
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapy for childhood acute lymphoblastic leukemia.
    Cassano WF; Eskenazi AE; Frantz CN
    Curr Opin Oncol; 1993 Jan; 5(1):42-52. PubMed ID: 8427893
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.
    Jackson RK; Irving JA; Veal GJ
    Br J Haematol; 2016 Apr; 173(1):13-24. PubMed ID: 26729065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proportion of long-term event-free survivors and lifetime of adult patients not cured after a standard acute lymphoblastic leukemia therapeutic program: adult acute lymphoblastic leukemia-94 trial.
    Le QH; Thomas X; Ecochard R; Iwaz J; Lhéritier V; Michallet M; Fiere D
    Cancer; 2007 May; 109(10):2058-67. PubMed ID: 17407135
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacogenomic effects on therapy for acute lymphoblastic leukemia in children.
    Wall AM; Rubnitz JE
    Pharmacogenomics J; 2003; 3(3):128-35. PubMed ID: 12815362
    [No Abstract]   [Full Text] [Related]  

  • 49. Genome study suggests new treatments for high-risk form of childhood leukemia.
    McBride D
    ONS Connect; 2012 Nov; 27(11):21. PubMed ID: 23316525
    [No Abstract]   [Full Text] [Related]  

  • 50. Phase II study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402.
    Azuma T; Tobinai K; Takeyama K; Shibata T; Hidaka M; Kurosawa M; Kasai M; Chou T; Fukushima N; Mukai K; Tsukasaki K; Shimoyama M;
    Jpn J Clin Oncol; 2012 May; 42(5):394-404. PubMed ID: 22422899
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute lymphoblastic leukaemia.
    Pui CH; Robison LL; Look AT
    Lancet; 2008 Mar; 371(9617):1030-43. PubMed ID: 18358930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Application of genome editing technology for the validation of pharmacogenomics in acute lymphoblastic leukemia].
    Akahane K
    Rinsho Ketsueki; 2022; 63(11):1566-1579. PubMed ID: 36476799
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clofarabine for the treatment of acute lymphoblastic leukemia.
    Jeha S; Kantarjian H
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):113-8. PubMed ID: 17288522
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
    Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
    Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term results of the AIEOP LNH-97 protocol for childhood lymphoblastic lymphoma.
    Pillon M; Aricò M; Mussolin L; Carraro E; Conter V; Sala A; Buffardi S; Garaventa A; D'Angelo P; Lo Nigro L; Santoro N; Piglione M; Lombardi A; Porta F; Cesaro S; Moleti ML; Casale F; Mura R; d'Amore ES; Basso G; Rosolen A
    Pediatr Blood Cancer; 2015 Aug; 62(8):1388-94. PubMed ID: 25755200
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia.
    Pui CH; Jeha S
    Nat Rev Drug Discov; 2007 Feb; 6(2):149-65. PubMed ID: 17268486
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia.
    Borst L; Wallerek S; Dalhoff K; Rasmussen KK; Wesenberg F; Wehner PS; Schmiegelow K
    Eur J Haematol; 2011 Jun; 86(6):477-83. PubMed ID: 21418106
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent progress in the treatment of acute lymphoblastic leukemia: clofarabine.
    Jeha S
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1137-44, viii. PubMed ID: 19825457
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.
    Evans WE; Relling MV; Rodman JH; Crom WR; Boyett JM; Pui CH
    N Engl J Med; 1998 Feb; 338(8):499-505. PubMed ID: 9468466
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia.
    Lugthart S; Cheok MH; den Boer ML; Yang W; Holleman A; Cheng C; Pui CH; Relling MV; Janka-Schaub GE; Pieters R; Evans WE
    Cancer Cell; 2005 Apr; 7(4):375-86. PubMed ID: 15837626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.